Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Next Science's quick ratio for the quarter that ended in Jun. 2025 was 1.25.
Next Science has a quick ratio of 1.25. It generally indicates good short-term financial strength.
The historical rank and industry rank for Next Science's Quick Ratio or its related term are showing as below:
ASX:NXS'
s Quick Ratio Range Over the Past 10 Years
Min: 1.25 Med: 5.34 Max: 21.29
Current: 1.25
During the past 7 years, Next Science's highest Quick Ratio was 21.29. The lowest was 1.25. And the median was 5.34.
ASX:NXS's Quick Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.44
vs ASX:NXS: 1.25
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Next Science Quick Ratio Related Terms
Next Science Quick Ratio Historical Data
* Premium members only.
The historical data trend for Next Science's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:NXS vs GCAN, PTPI, GRPS: Quick Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Next Science Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Next Science's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Next Science's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Next Science's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Next Science (ASX:NXS) has a Quick Ratio of 1.25 as of Jun. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Next Science and its competitors. This is 77% below median its historical median of 5.34. Over the past decade, Next Science's Quick Ratio has ranged from 1.25 to 21.29.
Is Next Science's Quick Ratio too high?
Next Science's current Quick Ratio of 1.25 is 77% below median its 10-year median of 5.34. Over the past 10 years, this metric has ranged from a low of 1.25 to a high of 21.29. The Drug Manufacturers industry median Quick Ratio is 1.44. Next Science's value of 1.25 is 13.2% below this industry median. Overall, Next Science has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Next Science's Quick Ratio compare to GCAN and PTPI?
Next Science's Quick Ratio of 1.25 can be compared against companies in the Drug Manufacturers industry. The industry median Quick Ratio is 1.44. Next Science's value of 1.25 is 13.2% below this benchmark. Historically, Next Science's own Quick Ratio has ranged from 1.25 to 21.29 over the past decade. While the company's 10-year median is 5.34 vs. the industry median of 1.44, Next Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.44, based on 994 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Next Science's current Quick Ratio of 1.25 is 13.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Next Science and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Next Science's current Quick Ratio is 1.25, which is 77% below median its own 10-year median of 5.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Next Science stock overvalued right now?
Next Science (ASX:NXS) has a current Quick Ratio of 1.25. The stock's GF Value™ is A$37.70, compared to a current price of A$0.15 — trading 99.6% below its estimated fair value. The current Quick Ratio is 1.25, which is 77% below median its 10-year median of 5.34 and 13.2% below the Drug Manufacturers industry median of 1.44. Next Science's overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Next Science (ASX:NXS), the current Quick Ratio is 1.25 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Next Science (ASX:NXS) Overvalued in 2026?
Based on GuruFocus' analysis, Next Science stock appears to be undervalued.
The current stock price of A$0.15 is trading 99.6% below its estimated GF Value™ of A$37.70.
Key valuation signals for ASX:NXS:
Quick Ratio: 1.25 (77% below median its 10-year median of 5.34)
GF Value™: A$37.70 vs. price of A$0.15 (99.6% below fair value)
Industry Position: 13.2% below the Drug Manufacturers median
No single metric tells the full story. See the ASX:NXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
25GF Score
Get the complete analysis for ASX:NXS
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NXS has been successfully added to your 
